233 related articles for article (PubMed ID: 24810970)
1. Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial.
Katzberg HD; Barnett C; Merkies IS; Bril V
Muscle Nerve; 2014 May; 49(5):661-5. PubMed ID: 24810970
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response to immunomodulation in patients with myasthenia gravis.
Katzberg HD; Barnett C; Bril V
Muscle Nerve; 2012 May; 45(5):648-52. PubMed ID: 22499090
[TBL] [Abstract][Full Text] [Related]
3. Surrogate therapeutic outcome measures in patients with myasthenia gravis.
Zinman L; Baryshnik D; Bril V
Muscle Nerve; 2008 Feb; 37(2):172-6. PubMed ID: 17918748
[TBL] [Abstract][Full Text] [Related]
4. IVIG Versus PLEX in the Treatment of Worsening Myasthenia Gravis: What is the Evidence?: A Critically Appraised Topic.
Dhawan PS; Goodman BP; Harper CM; Bosch PE; Hoffman-Snyder CR; Wellik KE; Wingerchuk DM; Demaerschalk BM
Neurologist; 2015 May; 19(5):145-8. PubMed ID: 25970838
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka KV
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
[TBL] [Abstract][Full Text] [Related]
6. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin.
Gajdos P; Chevret S
Ann N Y Acad Sci; 2008; 1132():271-5. PubMed ID: 18096850
[TBL] [Abstract][Full Text] [Related]
7. The quantitative myasthenia gravis score: comparison with clinical, electrophysiological, and laboratory markers.
Barnett C; Katzberg H; Nabavi M; Bril V
J Clin Neuromuscul Dis; 2012 Jun; 13(4):201-5. PubMed ID: 22622164
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.
Eienbröker C; Seitz F; Spengler A; Kurz H; Seipelt M; Sommer N; Oertel WH; Timmesfeld N; Tackenberg B
Muscle Nerve; 2014 Dec; 50(6):999-1004. PubMed ID: 24710856
[TBL] [Abstract][Full Text] [Related]
9. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis.
Barnett C; Wilson G; Barth D; Katzberg HD; Bril V
J Neurol Neurosurg Psychiatry; 2013 Jan; 84(1):94-7. PubMed ID: 23154126
[TBL] [Abstract][Full Text] [Related]
10. IVIG and PLEX in the treatment of myasthenia gravis.
Bril V; Barnett-Tapia C; Barth D; Katzberg HD
Ann N Y Acad Sci; 2012 Dec; 1275():1-6. PubMed ID: 23278570
[TBL] [Abstract][Full Text] [Related]
11. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.
Gajdos P; Tranchant C; Clair B; Bolgert F; Eymard B; Stojkovic T; Attarian S; Chevret S;
Arch Neurol; 2005 Nov; 62(11):1689-93. PubMed ID: 16286541
[TBL] [Abstract][Full Text] [Related]
12. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance.
Merkies IS; van Nes SI; Hanna K; Hughes RA; Deng C
J Neurol Neurosurg Psychiatry; 2010 Nov; 81(11):1194-9. PubMed ID: 20647554
[TBL] [Abstract][Full Text] [Related]
13. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial.
Zinman L; Ng E; Bril V
Neurology; 2007 Mar; 68(11):837-41. PubMed ID: 17353471
[TBL] [Abstract][Full Text] [Related]
14. Fcγ receptor polymorphisms do not predict response to intravenous immunoglobulin in myasthenia gravis.
Barnett C; Grinberg Y; Ghani M; Rogaeva E; Katzberg H; St George-Hyslop P; Bril V
J Clin Neuromuscul Dis; 2012 Sep; 14(1):1-6. PubMed ID: 22922574
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of therapeutic options used for myasthenia gravis.
Mandawat A; Kaminski HJ; Cutter G; Katirji B; Alshekhlee A
Ann Neurol; 2010 Dec; 68(6):797-805. PubMed ID: 21061395
[TBL] [Abstract][Full Text] [Related]
16. Juvenile myasthenia gravis.
Chiang LM; Darras BT; Kang PB
Muscle Nerve; 2009 Apr; 39(4):423-31. PubMed ID: 19229875
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin as treatment for myasthenia gravis: current evidence and outcomes.
Alabdali M; Barnett C; Katzberg H; Breiner A; Bril V
Expert Rev Clin Immunol; 2014 Dec; 10(12):1659-65. PubMed ID: 25331319
[TBL] [Abstract][Full Text] [Related]
18. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis.
Liu JF; Wang WX; Xue J; Zhao CB; You HZ; Lu JH; Gu Y
Ther Apher Dial; 2010 Apr; 14(2):153-60. PubMed ID: 20438536
[TBL] [Abstract][Full Text] [Related]
19. Baseline Decrement in Patients with Mild Myasthenia Gravis Predicts Immunomodulation Treatment.
Abraham A; Lovblom LE; Bril V
Can J Neurol Sci; 2019 Nov; 46(6):762-766. PubMed ID: 31322098
[TBL] [Abstract][Full Text] [Related]
20. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis.
Wolfe GI; Barohn RJ; Foster BM; Jackson CE; Kissel JT; Day JW; Thornton CA; Nations SP; Bryan WW; Amato AA; Freimer ML; Parry GJ;
Muscle Nerve; 2002 Oct; 26(4):549-52. PubMed ID: 12362423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
